ClinicalTrials.gg
CompletedNCT05310084Updated Jun 12, 2024Results posted

Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age

A Phase 3 interventional study of BNT162b2 and Placebo in SARS-CoV-2 Infection and COVID-19, sponsored by BioNTech SE. Completed at 26 sites in 2 countries. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-12.

Sponsored by BioNTech SE · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,134
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing BNT162 Vaccine in COVID-19 — 4 open to participants now, 6 under way, 1 of them phase 3. BNT162 Vaccine · COVID-19.

Enrollment
11th of 54
1,134 · median 575
Started
2022
with 7 others
Phase 3
18 of 54
1 open now
Registered
40th of 54
by date
Lead sponsor
20 of 54
BioNTech SE

Among the 54 studies testing BNT162 Vaccine in COVID-19, this one is the 11th largest by enrollment, is one of 8 that started in 2022, is one of 18 in phase 3, and was the 40th registered.

COVID-19

7,993 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

4 of the 54 studies testing BNT162 Vaccine in COVID-19 are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About BNT162 Vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing BNT162 Vaccine in COVID-19, or all of them as a file.
02

Study summary

This study will assess the safety and immunogenicity of a fourth dose (booster) of BNT162b2 when coadministered with SIIV compared to separate administration of the vaccines when given 1 month apart (SIIV followed by BNT162b2), in participants who have received 3 prior doses of 30 µg BNT162b2, with the third dose being at least 90 days before Visit 1 (Day 1).

  • Healthy adults 18 through 64 years of age will be randomized 1:1 to either the co-administration group, or the separate administration group
  • The duration of the study for each participant will be approximately 2 months
  • There are 3 scheduled study visits each about 1 month apart
  • The study will be conducted in New Zealand and Australia.
03

Conditions studied

  • SARS-CoV-2 Infection
  • COVID-19

Keywords

  • COVID-19
  • Coronavirus
  • Vaccine
  • SARS-CoV-2
  • RNA Vaccine
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants 18 through 64 years of age, inclusive, at the time of consent.
  2. Are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
  3. Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of study intervention.
  4. Have received 3 prior doses of 30 µg BNT162b2, with the third dose being at least 90 days before Visit 1 (Day 1). Documented confirmation of prior BNT162b2 receipt must be obtained prior to randomization.
  5. Capable of giving personal signed , which includes compliance with the requirements and restrictions listed in the ICD and in this protocol.

Exclusion criteria

Exclusion Criteria:

  1. Other medical or psychiatric condition, including recent (within the past year) or active suicidal ideation/behavior, or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  2. Allergy to egg proteins (egg or egg products) or chicken proteins.
  3. History of Guillain-Barré syndrome.
  4. History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s).
  5. A positive SARS-CoV-2 test result (either by NAAT or rapid antigen test) within 28 days of Visit 1 (Day 1).
  6. individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
  7. Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
  8. Women who are pregnant or breastfeeding.
  9. Vaccination with any influenza vaccine \<6 months before study intervention administration, or planned receipt of any licensed or nonstudy influenza vaccine during study participation.
  10. Individuals who receive treatment with radiotherapy or immunosuppressive therapy, including cytotoxic agents or systemic (if systemic corticosteroids are administered for ≥14 days at a dose of ≥20 mg/day of prednisone or equivalent), eg, for , or planned receipt throughout the study. Inhaled/nebulized, intra-articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.
  11. Receipt of blood/plasma products or immunoglobulin, from 60 days before study intervention administration or planned receipt throughout the study.
  12. Receipt of any passive antibody therapy specific to COVID-19 from 90 days before study intervention administration or planned receipt throughout the study.
  13. Prior receipt of any COVID-19 vaccine other than BNT162b2 or receipt of more than 3 prior doses of BNT162b2.
  14. Participation in other studies involving study intervention within 28 days prior to study entry and/or during study participation.
  15. Investigator site staff or Pfizer/BioNTech employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,134 participants (actual)

Study arms

  • Experimental
    Coadministration Group

    BNT162b2 and SIIV followed by placebo a month later

    Biological: BNT162b2 · Other: Placebo · Biological: Seasonal Inactivated Influenza Vaccine

  • Experimental
    Separate Administration Group

    Placebo and SIIV followed by BNT162b2 a month later

    Biological: BNT162b2 · Other: Placebo · Biological: Seasonal Inactivated Influenza Vaccine

Interventions

  • BiologicalBNT162b2

    Intramuscular injection

  • OtherPlacebo

    Saline intramuscular injection

  • BiologicalSeasonal Inactivated Influenza Vaccine

    SIIV intramuscular injection

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1

    Local reactions included redness, swelling, and pain at the injection site occurring at the BNT162b2 or placebo injection site. Local reactions were recorded by participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm) and graded as mild: greater than (\>) 2.0 to 5.0 cm, moderate: \>5.0 to 10.0 cm, severe: \>10.0 cm, and potentially life threatening (Grade 4): necrosis or exfoliative dermatitis. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity, severe: prevented daily activity, and potentially life threatening (Grade 4): emergency room visit or hospitalization for severe pain. Exact 2-sided confidence interval (CI), based on the Clopper and Pearson method was used.

    Time frame: Within 7 Days After Vaccination 1

  2. Percentage of Participants With Local Reactions Within 7 Days After Vaccination 2

    Local reactions included redness, swelling, and pain at the injection site occurring at the BNT162b2 or placebo injection site. Local reactions were recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm and graded as mild: greater than \>2.0 to 5.0 cm, moderate: \>5.0 to 10.0 cm, severe: \>10.0 cm, and potentially life threatening (Grade 4): necrosis or exfoliative dermatitis. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity, severe: prevented daily activity, and potentially life threatening (Grade 4): emergency room visit or hospitalization for severe pain. Exact 2-sided CI, based on the Clopper and Pearson method was used.

    Time frame: Within 7 Days After Vaccination 2

  3. Percentage of Participants With Systemic Events Within 7 Days After Vaccination 1

    Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, and new or worsened joint pain recorded by participants in an e-diary. Fever was defined as temperature: \>=38.0 degrees (deg) Celsius (C), and categorized as: \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C, and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, and new or worsened joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity, and severe: prevented daily routine activity. Vomiting graded as mild: 1 to 2 times in 24 hours(h), moderate: \>2 times in 24h, severe: required intravenous hydration, and grade 4: emergency room (ER) visit or hospitalization for hypotensive shock. Diarrhea graded as mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h, severe: 6 or more loose stools in 24h, and grade 4: ER visit or hospitalization for severe diarrhea.

    Time frame: Within 7 Days After Vaccination 1

  4. Percentage of Participants With Systemic Events Within 7 Days After Vaccination 2

    Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, and new or worsened joint pain recorded by participants in an e-diary. Fever was defined as temperature: \>=38.0 deg C, and categorized as: \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C, and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, and new or worsened joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity, and severe: prevented daily routine activity. Vomiting graded as mild: 1 to 2 times in 24h, moderate: \>2 times in 24h, severe: required intravenous hydration, and grade 4: ER visit or hospitalization for hypotensive shock. Diarrhea graded as mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h, severe: 6 or more loose stools in 24h, and grade 4: ER visit or hospitalization for severe diarrhea. Exact 2-sided CI, based on Clopper and Pearson method used.

    Time frame: Within 7 Days After Vaccination 2

  5. Percentage of Participants With Adverse Events Within 1 Month After Vaccination 1

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: Within 1 month after Vaccination 1

  6. Percentage of Participants With Adverse Events Within 1 Month After Vaccination 2

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: Within 1 month after Vaccination 2

  7. Percentage of Participants With Serious Adverse Events Within 1 Month After Vaccination 1

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Exact 2-sided CI was calculated using the Clopper and Pearson method. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; or that was considered to be an important medical event.

    Time frame: Within 1 Month After Vaccination 1

  8. Percentage of Participants With Serious Adverse Events Within 1 Month After Vaccination 2

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Exact 2-sided CI was calculated using the Clopper and Pearson method. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; or that was considered to be an important medical event.

    Time frame: Within 1 Month After Vaccination 2

  9. Geometric Mean Ratio (GMR) Based on Geometric Mean Concentration (GMC) of Full-Length S-binding Immunoglobulin G (IgG) at 1 Month After BNT162b2 Vaccination

    GMCs of full-length S-binding IgG level for the coadministration group and separate administration group were reported in this outcome measure in descriptive data section. GMC and the 2-sided 95% CI were calculated by exponentiating the LSMeans of the concentrations and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of vaccine group, age group, and the corresponding baseline assay results (log scale). Assay results below the LLOQ were set to 0.5\*LLOQ. Geometric mean ratio (GMR) was reported in the statistical analysis section and was calculated as ratio of GMCs in the coadministration group to the separate administration group. Here, "Number of participants analyzed" signifies number of participants evaluable for this outcome measure.

    Time frame: 1 Month After BNT162b2 vaccination

  10. Geometric Mean Ratio (GMR) Based on Geometric Mean Titer (GMT) of Strain-Specific Hemagglutination Inhibition (HAI) at 1 Month After SIIV Vaccination

    GMTs of strain-specific HAI titers for the coadministration group and separate administration group were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the LSMeans of the titers and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of vaccine group, age group, and the corresponding baseline assay results (log scale). Assay results below the LLOQ were set to 0.5\*LLOQ, and results above the ULOQ were set to ULOQ+1. Geometric mean ratio (GMR) was reported in the statistical analysis section and was calculated as ratio of GMT in the coadministration group to the separate administration group.

    Time frame: 1 Month After SIIV vaccination

Secondary outcomes

  1. Geometric Mean Concentration (GMC) of Full-Length S-binding IgG Levels Before Vaccination and 1 Month After BNT162b2 Vaccination

    GMCs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student's t-distribution). Assay results below the lower limit of quantitation (LLOQ) were set to 0.5\*LLOQ. Here, "Number of participants analyzed" signifies number of participants evaluable for this outcome measure''.

    Time frame: Before BNT162b2 vaccination, and 1 month After BNT162b2 vaccination

  2. Geometric Mean Fold Rise (GMFR) of Full-Length S-binding IgG Levels From Before Vaccination to 1 Month After BNT162b2 Vaccination

    GMFR was defined as the geometric mean of the ratios of IgG concentrations at 1 month after BNT162b2 vaccination to that before BNT162b2 vaccination. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student's t-distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. Here, "Number of participants analyzed" signifies number of participants evaluable for this outcome measure''.

    Time frame: From before BNT162b2 vaccination to 1 month After BNT162b2 vaccination

  3. Geometric Mean Titer (GMT) of SARS-CoV-2 Neutralizing Titers Before Vaccination and 1 Month After BNT162b2 Vaccination

    GMTs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student's t-distribution). Assay results below LLOQ were set to 0.5\*LLOQ. Here, "Number of participants analyzed" signifies number of participants evaluable for this outcome measure''. Analysis was performed in a subset of 100 participants from each group.

    Time frame: Before BNT162b2 vaccination, and 1 month after BNT162b2 vaccination

  4. Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Neutralizing Titers From Before Vaccination to 1 Month After BNT162b2 Vaccination

    GMFR was defined as the geometric mean of the ratios of SARS-CoV-2 neutralizing titers at 1 month after BNT162b2 vaccination to that before BNT162b2 vaccination. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student's t-distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. Here, "Number of participants analyzed" signifies number of participants evaluable for this outcome measure''. Analysis was performed in a subset of 100 participants from each group.

    Time frame: From before BNT162b2 vaccination to 1 month after BNT162b2 vaccination

  5. Geometric Mean Titer (GMT) of Strain-Specific HAI Titers Before Vaccination and 1 Month After SIIV Vaccination

    GMTs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student's t-distribution). Assay results below the LLOQ were set to 0.5\*LLOQ, and results above the ULOQ were set to ULOQ+1. The analysis was performed on the influenza strains: H1N1 A/Victoria, H3N2 A/Darwin, B/Austria, and B/Phuket.

    Time frame: Before SIIV vaccination, and 1 month after SIIV vaccination

  6. Geometric Mean Fold Rise (GMFR) of Strain-Specific HAI Titers From Before Vaccination to 1 Month After SIIV Vaccination

    GMFR was defined as ratio of the geometric mean of strain-specific HAI titers at 1 month after SIIV vaccination to the geometric mean of strain-specific HAI titers before SIIV vaccination. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student's t-distribution). Assay results below the LLOQ were set to 0.5\*LLOQ, and results above the ULOQ were set to ULOQ+1. The analysis was performed on the influenza strains: H1N1 A/Victoria, H3N2 A/Darwin, B/Austria, and B/Phuket.

    Time frame: From before vaccination to 1 month after SIIV vaccination

07

Results

Posted Nov 24, 2023

Participant flow

A total of 1165 participants were screened, out of which 31 were screen failures and 1134 were randomized into the study.

Participant flow — Overall Study
MilestoneCoadministration GroupSeparate Administration Group
Started568566
Vaccinated564564
Completed560555
Not completed811
Withdrew: Withdrawal by subject23
Withdrew: Participant availability04
Withdrew: Lost to follow-up11
Withdrew: Adverse event11
Withdrew: Randomized but not vaccinated42

Outcome measures

PrimaryPercentage of Participants With Local Reactions Within 7 Days After Vaccination 1

Local reactions included redness, swelling, and pain at the injection site occurring at the BNT162b2 or placebo injection site. Local reactions were recorded by participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm) and graded as mild: greater than (\>) 2.0 to 5.0 cm, moderate: \>5.0 to 10.0 cm, severe: \>10.0 cm, and potentially life threatening (Grade 4): necrosis or exfoliative dermatitis. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity, severe: prevented daily activity, and potentially life threatening (Grade 4): emergency room visit or hospitalization for severe pain. Exact 2-sided confidence interval (CI), based on the Clopper and Pearson method was used.

Time frame:
Within 7 Days After Vaccination 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1
Percentage of participantsCoadministration GroupSeparate Administration Group
Redness: Any7.6 (5.6 to 10.1)0.5 (0.1 to 1.6)
Redness: Mild6.2 (4.4 to 8.5)0.5 (0.1 to 1.6)
Redness: Moderate1.2 (0.5 to 2.5)0 (0.0 to 0.7)
Redness: Severe0.2 (0.0 to 1.0)0 (0.0 to 0.7)
Redness: Grade 40 (0.0 to 0.7)0 (0 to 0.7)
Swelling: Any9.2 (7.0 to 11.9)1.1 (0.4 to 2.3)
Swelling: Mild6.2 (4.4 to 8.5)0.4 (0.0 to 1.3)
Swelling: Moderate3.0 (1.8 to 4.8)0.7 (0.2 to 1.8)
Swelling: Severe0 (0.0 to 0.7)0 (0.0 to 0.7)
Swelling: Grade 40 (0.0 to 0.7)0 (0.0 to 0.7)
Pain at the injection site: Any86.2 (83.0 to 88.9)13.9 (11.1 to 17.0)
Pain at the injection site: Mild66.3 (62.2 to 70.2)13.5 (10.8 to 16.6)
Pain at the injection site: Moderate19.9 (16.6 to 23.4)0.4 (0.0 to 1.3)
Pain at the injection site: Severe0 (0.0 to 0.7)0 (0.0 to 0.7)
Pain at the injection site: Grade 40 (0.0 to 0.7)0 (0.0 to 0.7)
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Vaccination 2

Local reactions included redness, swelling, and pain at the injection site occurring at the BNT162b2 or placebo injection site. Local reactions were recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm and graded as mild: greater than \>2.0 to 5.0 cm, moderate: \>5.0 to 10.0 cm, severe: \>10.0 cm, and potentially life threatening (Grade 4): necrosis or exfoliative dermatitis. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity, severe: prevented daily activity, and potentially life threatening (Grade 4): emergency room visit or hospitalization for severe pain. Exact 2-sided CI, based on the Clopper and Pearson method was used.

Time frame:
Within 7 Days After Vaccination 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Vaccination 2
Percentage of participantsCoadministration GroupSeparate Administration Group
Redness: Any0.2 (0.0 to 1.0)4.7 (3.1 to 6.8)
Redness: Mild0.2 (0.0 to 1.0)4.3 (2.8 to 6.4)
Redness: Moderate0 (0.0 to 0.7)0.4 (0.0 to 1.3)
Redness: Severe0 (0.0 to 0.7)0 (0.0 to 0.7)
Redness: Grade 40 (0.0 to 0.7)0 (0.0 to 0.7)
Swelling: Any0.4 (0.0 to 1.3)8.9 (6.6 to 11.5)
Swelling: Mild0.4 (0.0 to 1.3)5.8 (4.0 to 8.1)
Swelling: Moderate0 (0.0 to 0.7)3.1 (1.8 to 4.9)
Swelling: Severe0 (0.0 to 0.7)0 (0.0 to 0.7)
Swelling: Grade 40 (0.0 to 0.7)0 (0.0 to 0.7)
Pain at the injection site: Any6.6 (4.7 to 9.0)84.4 (81.2 to 87.4)
Pain at the injection site: Mild6.3 (4.4 to 8.6)61.7 (57.5 to 65.7)
Pain at the injection site: Moderate0.4 (0.0 to 1.3)22.4 (19.0 to 26.1)
Pain at the injection site: Severe0 (0.0 to 0.7)0.4 (0.0 to 1.3)
Pain at the injection site: Grade 40 (0.0 to 0.7)0 (0.0 to 0.7)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Vaccination 1

Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, and new or worsened joint pain recorded by participants in an e-diary. Fever was defined as temperature: \>=38.0 degrees (deg) Celsius (C), and categorized as: \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C, and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, and new or worsened joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity, and severe: prevented daily routine activity. Vomiting graded as mild: 1 to 2 times in 24 hours(h), moderate: \>2 times in 24h, severe: required intravenous hydration, and grade 4: emergency room (ER) visit or hospitalization for hypotensive shock. Diarrhea graded as mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h, severe: 6 or more loose stools in 24h, and grade 4: ER visit or hospitalization for severe diarrhea.

Time frame:
Within 7 Days After Vaccination 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Vaccination 1
Percentage of participantsCoadministration GroupSeparate Administration Group
Fever: >=38.0 deg C2.0 (1.0 to 3.5)1.1 (0.4 to 2.3)
Fever: >=38.0 deg C to 38.4 deg C1.2 (0.5 to 2.5)0.4 (0.0 to 1.3)
Fever: >38.4 deg C to 38.9 deg C0.4 (0.0 to 1.3)0.4 (0.0 to 1.3)
Fever: >38.9 deg C to 40.0 deg C0.4 (0.0 to 1.3)0.4 (0.0 to 1.3)
Fever: >40.0 deg C0.0 (0.0 to 0.7)0.0 (0.0 to 0.7)
Fatigue: Any64.0 (59.9 to 68.0)42.1 (38.0 to 46.3)
Fatigue: Mild31.9 (28.1 to 35.9)24.7 (21.2 to 28.5)
Fatigue: Moderate30.9 (27.1 to 34.8)16.3 (13.4 to 19.7)
Fatigue: Severe1.2 (0.5 to 2.5)1.1 (0.4 to 2.3)
Fatigue: Grade 40 (0.0 to 0.7)0 (0.0 to 0.7)
Headache: Any47.2 (43.0 to 51.4)34.3 (30.4 to 38.4)
Headache: Mild28.2 (24.5 to 32.1)23.3 (19.9 to 27.0)
Headache: Moderate17.9 (14.8 to 21.3)10.3 (7.9 to 13.1)
Headache: Severe1.1 (0.4 to 2.3)0.7 (0.2 to 1.8)
Headache: Grade 40 (0.0 to 0.7)0 (0.0 to 0.7)
Chills: Any19.9 (16.6 to 23.4)6.2 (4.4 to 8.6)
Chills: Mild12.9 (10.3 to 16.0)4.3 (2.8 to 6.3)
Chills: Moderate6.0 (4.2 to 8.3)1.6 (0.7 to 3.0)
Chills: Severe0.9 (0.3 to 2.1)0.4 (0.0 to 1.3)
Chills: Grade 40 (0.0 to 0.7)0 (0.0 to 0.7)
Vomiting: Any2.7 (1.5 to 4.3)0.9 (0.3 to 2.1)
Vomiting: Mild2.3 (1.2 to 3.9)0.7 (0.2 to 1.8)
Vomiting: Moderate0.4 (0.0 to 1.3)0.2 (0.0 to 1.0)
Vomiting: Severe0 (0.0 to 0.7)0 (0.0 to 0.7)
Vomiting: Grade 40 (0.0 to 0.7)0 (0.0 to 0.7)
Diarrhea: Any11.5 (9.0 to 14.5)10.1 (7.8 to 12.9)
Diarrhea: Mild9.9 (7.6 to 12.7)8.9 (6.7 to 11.6)
Diarrhea: Moderate1.4 (0.6 to 2.8)1.2 (0.5 to 2.5)
Diarrhea: Severe0.2 (0.0 to 1.0)0 (0.0 to 0.7)
Diarrhea: Grade 40 (0.0 to 0.7)0 (0.0 to 0.7)
New or worsened muscle pain: Any27.7 (24.0 to 31.6)11.4 (8.9 to 14.3)
New or worsened muscle pain: Mild15.8 (12.9 to 19.1)6.2 (4.4 to 8.6)
New or worsened muscle pain: Moderate11.3 (8.8 to 14.3)5.0 (3.3 to 7.1)
New or worsened muscle pain: Severe0.5 (0.1 to 1.5)0.2 (0.0 to 1.0)
New or worsened muscle pain: Grade 40 (0.0 to 0.7)0 (0.0 to 0.7)
New or worsened joint pain: Any15.1 (12.2 to 18.3)5.3 (3.6 to 7.5)
New or worsened joint pain: Mild10.3 (7.9 to 13.1)2.7 (1.5 to 4.4)
New or worsened joint pain: Moderate4.8 (3.2 to 6.9)2.7 (1.5 to 4.4)
New or worsened joint pain: Severe0 (0.0 to 0.7)0 (0.0 to 0.7)
New or worsened joint pain: Grade 40 (0.0 to 0.7)0 (0.0 to 0.7)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Vaccination 2

Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, and new or worsened joint pain recorded by participants in an e-diary. Fever was defined as temperature: \>=38.0 deg C, and categorized as: \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C, and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, and new or worsened joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity, and severe: prevented daily routine activity. Vomiting graded as mild: 1 to 2 times in 24h, moderate: \>2 times in 24h, severe: required intravenous hydration, and grade 4: ER visit or hospitalization for hypotensive shock. Diarrhea graded as mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h, severe: 6 or more loose stools in 24h, and grade 4: ER visit or hospitalization for severe diarrhea. Exact 2-sided CI, based on Clopper and Pearson method used.

Time frame:
Within 7 Days After Vaccination 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Vaccination 2
Percentage of participantsCoadministration GroupSeparate Administration Group
Fever: >=38.0 deg C1.1 (0.4 to 2.3)1.6 (0.7 to 3.1)
Fever: >=38.0 deg C to 38.4 deg C0.5 (0.1 to 1.6)1.1 (0.4 to 2.3)
Fever: >38.4 deg C to 38.9 deg C0.5 (0.1 to 1.6)0.5 (0.1 to 1.6)
Fever: >38.9 deg C to 40.0 deg C0 (0.0 to 0.7)0 (0.0 to 0.7)
Fever: >40.0 deg C0. (0.0 to 0.7)0 (0.0 to 0.7)
Fatigue: Any21.7 (18.4 to 25.4)50.8 (46.6 to 55.1)
Fatigue: Mild12.4 (9.8 to 15.4)27.3 (23.6 to 31.2)
Fatigue: Moderate8.6 (6.4 to 11.3)22.1 (18.7 to 25.8)
Fatigue: Severe0.7 (0.2 to 1.8)1.4 (0.6 to 2.8)
Fatigue: Grade 40 (0.0 to 0.7)0 (0.0 to 0.7)
Headache: Any20.8 (17.5 to 24.4)37.8 (33.7 to 42.0)
Headache: Mild13.1 (10.4 to 16.2)25.0 (21.4 to 28.8)
Headache: Moderate7.5 (5.5 to 10.1)12.1 (9.5 to 15.1)
Headache: Severe0.2 (0.0 to 1.0)0.7 (0.2 to 1.8)
Headache: Grade 40 (0.0 to 0.7)0 (0.0 to 0.7)
Chills: Any3.4 (2.1 to 5.3)13.4 (10.7 to 16.5)
Chills: Mild2.3 (1.2 to 4.0)8.5 (6.3 to 11.1)
Chills: Moderate1.1 (0.4 to 2.3)4.7 (3.1 to 6.8)
Chills: Severe0 (0.0 to 0.7)0.2 (0.0 to 1.0)
Chills: Grade 40 (0.0 to 0.7)0 (0.0 to 0.7)
Vomiting: Any1.1 (0.4 to 2.3)2.4 (1.3 to 4.0)
Vomiting: Mild0.7 (0.2 to 1.8)1.8 (0.9 to 3.3)
Vomiting: Moderate0.4 (0.0 to 1.3)0.5 (0.1 to 1.6)
Vomiting: Severe0 (0.0 to 0.7)0 (0.0 to 0.7)
Vomiting: Grade 40 (0.0 to 0.7)0 (0.0 to 0.7)
Diarrhea: Any4.5 (2.9 to 6.6)6.5 (4.6 to 8.9)
Diarrhea: Mild3.8 (2.3 to 5.7)5.2 (3.5 to 7.4)
Diarrhea: Moderate0.7 (0.2 to 1.8)0.9 (0.3 to 2.1)
Diarrhea: Severe0 (0.0 to 0.7)0.4 (0.0 to 1.3)
Diarrhea: Grade 40 (0.0 to 0.7)0 (0.0 to 0.7)
New or worsened muscle pain: Any5.2 (3.5 to 7.4)23.5 (20.0 to 27.3)
New or worsened muscle pain: Mild2.7 (1.5 to 4.4)12.8 (10.2 to 15.9)
New or worsened muscle pain: Moderate2.5 (1.4 to 4.2)10.5 (8.1 to 13.3)
New or worsened muscle pain: Severe0 (0.0 to 0.7)0.2 (0.0 to 1.0)
New or worsened muscle pain: Grade 40 (0.0 to 0.7)0 (0.0 to 0.7)
New or worsened joint pain: Any3.4 (2.1 to 5.3)9.8 (7.4 to 12.5)
New or worsened joint pain: Mild2.0 (1.0 to 3.5)5.6 (3.8 to 7.9)
New or worsened joint pain: Moderate1.4 (0.6 to 2.8)4.2 (2.7 to 6.2)
New or worsened joint pain: Severe0 (0.0 to 0.7)0 (0.0 to 0.7)
New or worsened joint pain: Grade 40 (0.0 to 0.7)0 (0.0 to 0.7)
PrimaryPercentage of Participants With Adverse Events Within 1 Month After Vaccination 1

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
Within 1 month after Vaccination 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Adverse Events Within 1 Month After Vaccination 1
Percentage of participantsCoadministration GroupSeparate Administration Group
Percentage of Participants With Adverse Events Within 1 Month After Vaccination 131.6 (27.7 to 35.6)30.5 (26.7 to 34.5)
PrimaryPercentage of Participants With Adverse Events Within 1 Month After Vaccination 2

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
Within 1 month after Vaccination 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Adverse Events Within 1 Month After Vaccination 2
Percentage of participantsCoadministration GroupSeparate Administration Group
Percentage of Participants With Adverse Events Within 1 Month After Vaccination 229.0 (25.3 to 32.9)25.1 (21.6 to 29.0)
PrimaryPercentage of Participants With Serious Adverse Events Within 1 Month After Vaccination 1

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Exact 2-sided CI was calculated using the Clopper and Pearson method. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; or that was considered to be an important medical event.

Time frame:
Within 1 Month After Vaccination 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Serious Adverse Events Within 1 Month After Vaccination 1
Percentage of participantsCoadministration GroupSeparate Administration Group
Percentage of Participants With Serious Adverse Events Within 1 Month After Vaccination 10.4 (0.0 to 1.3)0.2 (0.0 to 1.0)
PrimaryPercentage of Participants With Serious Adverse Events Within 1 Month After Vaccination 2

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Exact 2-sided CI was calculated using the Clopper and Pearson method. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; or that was considered to be an important medical event.

Time frame:
Within 1 Month After Vaccination 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Serious Adverse Events Within 1 Month After Vaccination 2
Percentage of participantsCoadministration GroupSeparate Administration Group
Percentage of Participants With Serious Adverse Events Within 1 Month After Vaccination 20.5 (0.1 to 1.6)0.7 (0.2 to 1.8)
PrimaryGeometric Mean Ratio (GMR) Based on Geometric Mean Concentration (GMC) of Full-Length S-binding Immunoglobulin G (IgG) at 1 Month After BNT162b2 Vaccination

GMCs of full-length S-binding IgG level for the coadministration group and separate administration group were reported in this outcome measure in descriptive data section. GMC and the 2-sided 95% CI were calculated by exponentiating the LSMeans of the concentrations and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of vaccine group, age group, and the corresponding baseline assay results (log scale). Assay results below the LLOQ were set to 0.5\*LLOQ. Geometric mean ratio (GMR) was reported in the statistical analysis section and was calculated as ratio of GMCs in the coadministration group to the separate administration group. Here, "Number of participants analyzed" signifies number of participants evaluable for this outcome measure.

Time frame:
1 Month After BNT162b2 vaccination
Reported as:
Geometric mean · Units per millilitre (U/mL)
Geometric Mean Ratio (GMR) Based on Geometric Mean Concentration (GMC) of Full-Length S-binding Immunoglobulin G (IgG) at 1 Month After BNT162b2 Vaccination
Units per millilitre (U/mL)Coadministration GroupSeparate Administration Group
Geometric Mean Ratio (GMR) Based on Geometric Mean Concentration (GMC) of Full-Length S-binding Immunoglobulin G (IgG) at 1 Month After BNT162b2 Vaccination13767.8 (13110.0 to 14458.6)16644.5 (15774.7 to 17562.3)
Statistical analysis
  • Coadministration Group vs Separate Administration Group · Gmr: 0.83 · 95% CI 0.77 to 0.89GMRs and 95% CIs were calculated by exponentiating LSmeans difference of logarithms of concentrations (coadmin group-separate admin group), corresponding CIs based on analysis of log transformed assay results using a linear regression model.
PrimaryGeometric Mean Ratio (GMR) Based on Geometric Mean Titer (GMT) of Strain-Specific Hemagglutination Inhibition (HAI) at 1 Month After SIIV Vaccination

GMTs of strain-specific HAI titers for the coadministration group and separate administration group were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the LSMeans of the titers and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of vaccine group, age group, and the corresponding baseline assay results (log scale). Assay results below the LLOQ were set to 0.5\*LLOQ, and results above the ULOQ were set to ULOQ+1. Geometric mean ratio (GMR) was reported in the statistical analysis section and was calculated as ratio of GMT in the coadministration group to the separate administration group.

Time frame:
1 Month After SIIV vaccination
Reported as:
Geometric mean · Titer
Geometric Mean Ratio (GMR) Based on Geometric Mean Titer (GMT) of Strain-Specific Hemagglutination Inhibition (HAI) at 1 Month After SIIV Vaccination
TiterCoadministration GroupSeparate Administration Group
B/Austria80.1 (71.7 to 89.6)89.7 (80.0 to 100.7)
B/Phuket81.3 (74.4 to 88.9)81.3 (74.2 to 89.2)
H1N1 A/Victoria301.7 (273.1 to 333.4)316.5 (285.5 to 350.9)
H3N2 A/Darwin226.8 (207.2 to 248.3)235.6 (214.6 to 258.7)
Statistical analysis
  • Coadministration Group vs Separate Administration Group · Geometric mean ratio: 0.89 · 95% CI 0.77 to 1.04GMRs and 95% CIs were calculated by exponentiating LSmeans difference of logarithms of titers (coadministration group-separate administration group), corresponding CIs based on analysis of log transformed assay results using a linear regression model
  • Coadministration Group vs Separate Administration Group · Gmr: 1.00 · 95% CI 0.89 to 1.13GMRs and 95% CIs were calculated by exponentiating LSmeans difference of logarithms of titers (coadministration group-separate administration group), corresponding CIs based on analysis of log transformed assay results using a linear regression model
  • Coadministration Group vs Separate Administration Group · Gmr: 0.95 · 95% CI 0.83 to 1.09GMRs and 95% CIs were calculated by exponentiating LSmeans difference of logarithms of titers (coadministration group-separate administration group), corresponding CIs based on analysis of log transformed assay results using a linear regression model
  • Coadministration Group vs Separate Administration Group · Gmr: 0.96 · 95% CI 0.85 to 1.09GMRs and 95% CIs were calculated by exponentiating LSmeans difference of logarithms of titers (coadministration group-separate administration group), corresponding CIs based on analysis of log transformed assay results using a linear regression model
SecondaryGeometric Mean Concentration (GMC) of Full-Length S-binding IgG Levels Before Vaccination and 1 Month After BNT162b2 Vaccination

GMCs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student's t-distribution). Assay results below the lower limit of quantitation (LLOQ) were set to 0.5\*LLOQ. Here, "Number of participants analyzed" signifies number of participants evaluable for this outcome measure''.

Time frame:
Before BNT162b2 vaccination, and 1 month After BNT162b2 vaccination
Reported as:
Geometric mean · Units per millilitre (U/mL)
Geometric Mean Concentration (GMC) of Full-Length S-binding IgG Levels Before Vaccination and 1 Month After BNT162b2 Vaccination
Units per millilitre (U/mL)Coadministration GroupSeparate Administration Group
Before BNT162b2 Vaccination5520.3 (5034.7 to 6052.8)5272.3 (4704.3 to 5909.0)
1 Month After BNT162b2 Vaccination13806.5 (12838.9 to 14847.0)16254.6 (15035.5 to 17572.5)
SecondaryGeometric Mean Fold Rise (GMFR) of Full-Length S-binding IgG Levels From Before Vaccination to 1 Month After BNT162b2 Vaccination

GMFR was defined as the geometric mean of the ratios of IgG concentrations at 1 month after BNT162b2 vaccination to that before BNT162b2 vaccination. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student's t-distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. Here, "Number of participants analyzed" signifies number of participants evaluable for this outcome measure''.

Time frame:
From before BNT162b2 vaccination to 1 month After BNT162b2 vaccination
Reported as:
Geometric mean · Fold rise
Geometric Mean Fold Rise (GMFR) of Full-Length S-binding IgG Levels From Before Vaccination to 1 Month After BNT162b2 Vaccination
Fold riseCoadministration GroupSeparate Administration Group
Geometric Mean Fold Rise (GMFR) of Full-Length S-binding IgG Levels From Before Vaccination to 1 Month After BNT162b2 Vaccination2.5 (2.4 to 2.7)3.1 (2.9 to 3.3)
SecondaryGeometric Mean Titer (GMT) of SARS-CoV-2 Neutralizing Titers Before Vaccination and 1 Month After BNT162b2 Vaccination

GMTs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student's t-distribution). Assay results below LLOQ were set to 0.5\*LLOQ. Here, "Number of participants analyzed" signifies number of participants evaluable for this outcome measure''. Analysis was performed in a subset of 100 participants from each group.

Time frame:
Before BNT162b2 vaccination, and 1 month after BNT162b2 vaccination
Reported as:
Geometric mean · Titer
Geometric Mean Titer (GMT) of SARS-CoV-2 Neutralizing Titers Before Vaccination and 1 Month After BNT162b2 Vaccination
TiterCoadministration GroupSeparate Administration Group
Before BNT162b2 Vaccination2755.9 (2107.6 to 3603.4)2421.2 (1780.1 to 3293.3)
1 Month After BNT162b2 Vaccination6773.9 (5545.0 to 8275.3)7886.6 (6264.9 to 9928.2)
SecondaryGeometric Mean Fold Rise (GMFR) of SARS-CoV-2 Neutralizing Titers From Before Vaccination to 1 Month After BNT162b2 Vaccination

GMFR was defined as the geometric mean of the ratios of SARS-CoV-2 neutralizing titers at 1 month after BNT162b2 vaccination to that before BNT162b2 vaccination. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student's t-distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. Here, "Number of participants analyzed" signifies number of participants evaluable for this outcome measure''. Analysis was performed in a subset of 100 participants from each group.

Time frame:
From before BNT162b2 vaccination to 1 month after BNT162b2 vaccination
Reported as:
Geometric mean · Fold rise
Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Neutralizing Titers From Before Vaccination to 1 Month After BNT162b2 Vaccination
Fold riseCoadministration GroupSeparate Administration Group
Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Neutralizing Titers From Before Vaccination to 1 Month After BNT162b2 Vaccination2.5 (2.1 to 2.9)3.3 (2.7 to 3.9)
SecondaryGeometric Mean Titer (GMT) of Strain-Specific HAI Titers Before Vaccination and 1 Month After SIIV Vaccination

GMTs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student's t-distribution). Assay results below the LLOQ were set to 0.5\*LLOQ, and results above the ULOQ were set to ULOQ+1. The analysis was performed on the influenza strains: H1N1 A/Victoria, H3N2 A/Darwin, B/Austria, and B/Phuket.

Time frame:
Before SIIV vaccination, and 1 month after SIIV vaccination
Reported as:
Geometric mean · Titer
Geometric Mean Titer (GMT) of Strain-Specific HAI Titers Before Vaccination and 1 Month After SIIV Vaccination
TiterCoadministration GroupSeparate Administration Group
B/Austria: Before Vaccination13.0 (11.7 to 14.5)12.7 (11.5 to 14.1)
B/Austria: 1 Month After SIIV Vaccination72.4 (64.2 to 81.7)78.3 (69.3 to 88.5)
B/Phuket: Before Vaccination26.4 (23.8 to 29.4)25.7 (23.0 to 28.6)
B/Phuket: 1 Month After SIIV Vaccination87.4 (79.7 to 95.7)86.3 (78.4 to 94.9)
H1N1 A/Victoria: Before Vaccination57.0 (49.5 to 65.6)56.3 (48.9 to 64.7)
H1N1 A/Victoria: 1 Month After SIIV Vaccination344.3 (312.4 to 379.3)362.3 (326.8 to 401.6)
H3N2 A/Darwin: Before Vaccination39.5 (35.6 to 43.7)38.4 (34.5 to 42.8)
H3N2 A/Darwin: 1 Month After SIIV Vaccination230.6 (209.5 to 253.8)242.2 (221.2 to 265.2)
SecondaryGeometric Mean Fold Rise (GMFR) of Strain-Specific HAI Titers From Before Vaccination to 1 Month After SIIV Vaccination

GMFR was defined as ratio of the geometric mean of strain-specific HAI titers at 1 month after SIIV vaccination to the geometric mean of strain-specific HAI titers before SIIV vaccination. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student's t-distribution). Assay results below the LLOQ were set to 0.5\*LLOQ, and results above the ULOQ were set to ULOQ+1. The analysis was performed on the influenza strains: H1N1 A/Victoria, H3N2 A/Darwin, B/Austria, and B/Phuket.

Time frame:
From before vaccination to 1 month after SIIV vaccination
Reported as:
Geometric mean · Fold rise
Geometric Mean Fold Rise (GMFR) of Strain-Specific HAI Titers From Before Vaccination to 1 Month After SIIV Vaccination
Fold riseCoadministration GroupSeparate Administration Group
B/Austria5.5 (4.9 to 6.2)6.3 (5.6 to 7.1)
B/Phuket3.3 (2.9 to 3.7)3.4 (3.0 to 3.8)
H1N1 A/Victoria6.0 (5.1 to 7.0)6.4 (5.5 to 7.5)
H3N2 A/Darwin5.9 (5.3 to 6.6)6.3 (5.6 to 7.1)

Adverse events

Collected over AEs and SAEs: From Day 1 (Visit 1) to 1 month after last dose of study vaccine (approximately 2 months after Visit 1 [Day1]); Local reactions (at the BNT162b2/placebo injection site) and systemic events: Within 7 days after each vaccination. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Coadministration Group (Visit 1)0/564 (0%)2/564 (0.4%)532/564 (94.3%)
Coadministration Group (Visit 2)0/562 (0%)3/562 (0.5%)261/562 (46.4%)
Separate Administration Group (Visit 1)0/564 (0%)1/564 (0.2%)364/564 (64.5%)
Separate Administration Group (Visit 2)0/557 (0%)4/557 (0.7%)502/557 (90.1%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventCoadministration Group (Visit 1)Coadministration Group (Visit 2)Separate Administration Group (Visit 1)Separate Administration Group (Visit 2)
Atrial fibrillationCardiac disorders0/5640/5620/5641/557
ConcussionInjury, poisoning and procedural complications0/5640/5620/5641/557
Ligament sprainInjury, poisoning and procedural complications0/5640/5620/5641/557
PneumocephalusInjury, poisoning and procedural complications0/5640/5620/5641/557
Skull fractureInjury, poisoning and procedural complications0/5640/5620/5641/557
Musculoskeletal chest painMusculoskeletal and connective tissue disorders1/5640/5620/5641/557
Intestinal perforationGastrointestinal disorders0/5641/5620/5640/557
CostochondritisMusculoskeletal and connective tissue disorders0/5641/5620/5640/557
Malignant melanoma stage IINeoplasms benign, malignant and unspecified (incl cysts and polyps)0/5641/5620/5640/557
Abscess limbInfections and infestations0/5640/5621/5640/557
Most frequent other events
Showing 10 of 15
Most frequent other events
EventCoadministration Group (Visit 1)Coadministration Group (Visit 2)Separate Administration Group (Visit 1)Separate Administration Group (Visit 2)
Injection site painGeneral disorders486/56437/56278/564467/557
FatigueGeneral disorders361/564121/562237/564281/557
HeadacheNervous system disorders266/564116/562193/564209/557
ChillsGeneral disorders112/56419/56235/56474/557
DiarrhoeaGastrointestinal disorders65/56425/56257/56436/557
COVID-19Infections and infestations46/56463/56256/56448/557
Injection site swellingGeneral disorders52/5642/5626/56449/557
Injection site erythemaGeneral disorders43/5641/5623/56426/557
Upper respiratory tract infectionInfections and infestations27/56431/56224/56422/557
Injection site painGeneral disorders16/5641/56214/5641/557

Baseline characteristics

Safety population included all participants who received any of the study intervention.

Age, Continuous
Age, Continuous(Years)Coadministration GroupSeparate Administration GroupTotal
Mean39.7 ± 13.2039.8 ± 13.5239.7 ± 13.35
Sex: Female, Male
Sex: Female, Male(Participants)Coadministration GroupSeparate Administration GroupTotal
Female356361717
Male208203411
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Coadministration GroupSeparate Administration GroupTotal
Hispanic or Latino5914
Not Hispanic or Latino5395371076
Unknown or Not Reported201838
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Coadministration GroupSeparate Administration GroupTotal
American Indian or Alaska Native000
Asian7366139
Native Hawaiian or Other Pacific Islander263662
Black or African American123
White446439885
More than one race11011
Unknown or Not Reported171128
08

Study locations

26 sites
  • Northern Beaches Clinical Research
    Brookvale, New South Wales 2100, Australia
  • Australian Clinical Research Network
    Sydney, New South Wales NSW 2035, Australia
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
  • Paratus Clinical Research Brisbane
    Albion, Queensland 4010, Australia
  • AusTrials - Wellers Hill
    Wellers Hill, Queensland 4121, Australia
  • Emeritus Research
    Camberwell, Victoria 3124, Australia
  • Barwon Health
    Geelong, Victoria 3220, Australia
  • New Zealand Clinical Research (Auckland)
    Grafton, Auckland 1010, New Zealand
  • Optimal Clinical Trials
    Grafton, Auckland 1010, New Zealand
  • Southern Clinical Trials Totara
    New Lynn, Auckland 0600, New Zealand
  • Lakeland Clinical Trials Culloden
    Papamoa Beach, BAY OF Plenty 3118, New Zealand
  • Pacific Clinical Research Network - Rotorua
    Rotorua, BAY OF Plenty 3010, New Zealand
  • P3 Research - Tauranga
    Tauranga, BAY OF Plenty 3110, New Zealand
  • New Zealand Clinical Research (Christchurch)
    Christchurch, Canterbury 8011, New Zealand
  • Pacific Clinical Research Network - Forte
    Christchurch, Canterbury 8013, New Zealand
  • P3 Research - Hawke's Bay
    Havelock North, Hawke's BAY 4130, New Zealand
  • P3 Research - Palmerston North
    Palmerston North, Manawatu-wanganui 4414, New Zealand
  • Lakeland Clinical Trials Waikato
    Hamilton, Waikato 3200, New Zealand
  • Lakeland Clinical Trials Wellington
    Ebdentown. Upper Hutt, Wellington 5018, New Zealand
  • P3 Research - Kapiti
    Paraparaumu, Wellington 5032, New Zealand
  • Southern Clinical Trials Waitemata Ltd
    Auckland, 0626, New Zealand
  • Aotearoa Clinical Trials
    Auckland, 2025, New Zealand
  • Middlemore Clinical Trials
    Auckland, 2025, New Zealand
  • Southern Clinical Trials Tasman
    Nelson, 7011, New Zealand
  • Capital, Coast and Hutt Valley District - Wellington Regional Hospital
    Wellington, 6021, New Zealand
  • P3 Research - Wellington
    Wellington, 6021, New Zealand
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Oct 2022, 5 months.

Results were first posted in Nov 2023, 1 year 1 month after primary completion.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 5 months is below that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2022
First posted
Apr 4, 2022
StartActual
Apr 20, 2022
Primary completionActual
Oct 5, 2022
CompletionActual
Oct 5, 2022
Results first posted
Nov 24, 2023
Last update
Jun 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05310084
Lead sponsor
BioNTech SE
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Apr 4, 2022
Start date
Apr 20, 2022
Primary completion
Oct 5, 2022
Completion
Oct 5, 2022
Results posted
Nov 24, 2023
Last update
Jun 12, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BNT162 Vaccine

Start the discussion